YU-2024-HYPERFRAC

NCT03214003 📎

Regimen

Experimental
VMAT 54 Gy in 30 fractions (twice-daily, simultaneous integrated boost) + platinum/etoposide
Control
VMAT 45 Gy in 30 fractions (twice-daily) + platinum/etoposide

Population

LS-SCLC patients age 18-70, ECOG 0-1, enrolled at 16 Chinese public hospitals Jun 2017 - Apr 2021

Key finding

mOS 60.7 mo (54 Gy) vs 39.5 mo (45 Gy); HR 0.55 (95% CI 0.37-0.72, p=0.003); grade 3-4 esophagitis 13% vs 12% (p=0.84); trial terminated early for clinical benefit

Source: PMID 39146944

Timeline

    Guideline citations

    • NCCN SCLC (p.6)
    • CSCO SCLC 2025 (p.48)⚠️ OCR source